NCT05028504

A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer

A Single-arm, Open-label, Multi-cohort, Multi-center Phase II Clinical Study of Anlotinib Combined With Penpulimab in the Treatment of Recurrent or Metastatic Gynecological Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (estimated)
• Sponsor: Sichuan Cancer Hospital and Research Institute · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23 ovarian cancer，37 endometrial cancer，26 cervical cancer.

Conditions

• Gynecological Cancer

Interventions

Type	Name	Description
DRUG	Penpulimab	Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
DRUG	Anlotinib	A multi-target receptor tyrosine kinase inhibitor

Timeline

• Start date: 2022-05-10
• Primary completion: 2024-12-31
• Completion: 2025-12-31
• First posted: 2021-08-31
• Last updated: 2023-12-27

Locations

6 sites across 1 country: China